Issue
Number 532
June 13, 2005
CONTENTS OF THIS ISSUE
- FDA approves a new combination vaccine to help protect
adolescents and adults against whooping cough
- New: AMA's primer will help physicians improve
immunization rates, especially among minority populations
- New: CDC issues guidelines for preventing and
controlling influenza transmission in long-term-care facilities
- New: IAC develops a professional-education piece on the
use of standing orders to improve adult vaccination rates
- New VIS translations: VISs for five vaccines now
available in Burmese
- MMWR corrects data reported on total mortality and
influenza and pneumonia mortality between April 1-May 27, 2005
----------------------------------------------------------
Back to Top
---------------------------------------------------------------
ABBREVIATIONS: AAFP, American Academy of Family Physicians; AAP, American
Academy of Pediatrics; ACIP, Advisory Committee on Immunization Practices;
CDC, Centers for Disease Control and Prevention; FDA, Food and Drug
Administration; IAC, Immunization Action Coalition; MMWR, Morbidity and
Mortality Weekly Report; NIP, National Immunization Program; VIS, Vaccine
Information Statement; VPD, vaccine-preventable disease; WHO, World Health
Organization.
---------------------------------------------------------------
(1 of 6)
June 13, 2005
FDA APPROVES A NEW COMBINATION VACCINE TO HELP PROTECT ADOLESCENTS AND
ADULTS AGAINST WHOOPING COUGH
On June 10, FDA approved Adacel, a vaccine for single-booster immunization
against pertussis, in combination with tetanus and diphtheria. It is a
Tetanus Toxoid (T), Reduced Diphtheria Toxoid (d), and Acellular Pertussis
Vaccine (ap), Adsorbed. Manufactured by Aventis Pasteur Limited, Toronto,
Adacel is intended for use in individuals 11-64 years of age. It is
anticipated that ACIP will discuss Adacel's use at its June 29-30 meeting.
Adacel is the first vaccine approved as a pertussis booster for adults.
Vaccines for prevention of tetanus and diphtheria (Td vaccine) for adults
and adolescents have been around for years. On May 3, FDA approved Boostrix,
a similar vaccine manufactured by GlaxoSmithKline, for use in adolescents
ages 10-18 years.
Pertussis, a highly communicable and potentially serious illness in
adolescents and adults, can cause prolonged cough and missed days at school
and work. In young infants, pertussis is more frequently severe and can be
fatal, particularly in those too young to be fully vaccinated. Since 1980,
the rates of reported pertussis cases have been increasing in adolescents
and adults, as well as in young infants. Adolescents and adults have been
implicated as the source of pertussis infection for susceptible young
infants and other family members.
To access the FDA Talk Paper, go to:
http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01361.html
To access the prescribing information, go to:
http://www.fda.gov/cber/label/tdapave061005LB.pdf
To access the licensing action, go to:
http://www.fda.gov/cber/products/tdapave061005.htm
To access the FDA approval letter, go to:
http://www.fda.gov/cber/approvltr/tdapave061005L.htm
---------------------------------------------------------------
Back to Top
(2 of 6)
June 13, 2005
NEW: AMA'S PRIMER WILL HELP PHYSICIANS IMPROVE IMMUNIZATION RATES,
ESPECIALLY AMONG MINORITY POPULATIONS
The American Medical Association (AMA) recently published a physician
primer, "Improving Immunization: Addressing Racial and Ethnic Populations."
It is the fourth primer in the AMA's series Roadmaps for Clinical Practice.
A collaborative endeavor between the AMA and CDC, the Roadmaps series is
intended to help physicians adapt to changes in the medical environment and
integrate disease prevention and health promotion into routine clinical
care.
The immunization primer has four main components: overview, childhood and
adolescent immunizations, adult immunizations, and resources for physicians
and patients. It also has a continuing medical education activity and a
program evaluation form.
To download the components, go to:
http://www.ama-assn.org/ama/pub/category/9958.html
You can also order a complimentary copy of the primer in print (hardcover
binder) or on CD-ROM. To order, call (312) 464-2456 or fax your request to
(312) 464-5842.
---------------------------------------------------------------
Back to Top
(3 of 6)
June 13, 2005
NEW: CDC ISSUES GUIDELINES FOR PREVENTING AND CONTROLLING INFLUENZA
TRANSMISSION IN LONG-TERM-CARE FACILITIES
CDC recently posted new guidelines on its influenza web section. Titled
"Guidelines and Recommendations: Infection Control Measures for Preventing
and Controlling Influenza Transmission in Long-Term-Care Facilities," it
covers influenza transmission, prevention and control measures, vaccination,
and infection control measures in long-term-care settings.
To access a ready-to-print (PDF) version, go to:
http://www.cdc.gov/flu/professionals/infectioncontrol/pdf/longtermcare.pdf
To access a web-text (HTML) version, go to:
http://www.cdc.gov/flu/professionals/infectioncontrol/longtermcare.htm
---------------------------------------------------------------
Back to Top
(4 of 6)
June 13, 2005
NEW: IAC DEVELOPS A PROFESSIONAL-EDUCATION PIECE ON THE USE OF STANDING
ORDERS TO IMPROVE ADULT VACCINATION RATES
In May, IAC created a three-page professional-education piece "Standing
orders for administering eight vaccines to adults and a protocol for
managing anaphylaxis." The piece has links to prototype standing orders
protocols that providers can adapt for administering vaccines commonly given
to some or all adults.
ACIP reports that the use of standing orders is documented to have "improved
vaccination rates among adults" and strongly encourages their use. IAC
created the standing orders prototypes with the intent that providers will
adapt them for use in private practices, health-maintenance organizations,
clinics, hospitals, long-term-care facilities, and other healthcare
settings.
The newly developed piece has links to standing orders prototypes for the
following vaccines: influenza, meningococcal, tetanus-diphtheria (Td),
varicella, measles-mumps-rubella (MMR), pneumococcal polysaccharide (PPV),
hepatitis B, and hepatitis A. It also includes a link to a prototype
protocol for managing anaphylactic reactions to adult vaccines.
To access a ready-to-print (PDF) version of the piece, go to:
http://www.immunize.org/catg.d/p3089.pdf
Note: No web-text HTML version is available.
For more information on the successful use of standing orders in adult
vaccination, see the ACIP recommendation and report "Use of Standing Orders
Programs to Increase Adult Vaccination Rates: Recommendations of the
Advisory Committee on Immunization Practices. MMWR 2000; 49(RR01):15-26. You
can access it by going to
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4901a2.htm
---------------------------------------------------------------
Back to Top
(5 of 6)
June 13, 2005
NEW VIS TRANSLATIONS: VISs FOR FIVE VACCINES NOW AVAILABLE IN BURMESE
The current versions of the VISs for the following vaccines are now
available in Burmese: varicella; diphtheria-tetanus-pertussis (DTaP);
Haemophilus influenzae type b (Hib); hepatitis B; and measles-mumps-rubella
(MMR). IAC gratefully acknowledges the California Department of Health
Services for the translations.
VARICELLA VACCINE VIS (dated 12/16/98)
To obtain a ready-to-print (PDF) version of the VIS for varicella vaccine in
Burmese, go to:
http://www.immunize.org/vis/bu_var98.pdf
To obtain it in English, go to:
http://www.immunize.org/vis/varic99.pdf
DTaP VACCINE VIS (dated 7/30/01)
To obtain a ready-to-print (PDF) version of the VIS for DTaP vaccine in
Burmese, go to:
http://www.immunize.org/vis/budtap01.pdf
To obtain it in English, go to:
http://www.immunize.org/vis/dtap01.pdf
Hib VACCINE VIS (dated 12/16/98)
To obtain a ready-to-print (PDF) version of the VIS for Hib vaccine in
Burmese, go to:
http://www.immunize.org/vis/bu_hib98.pdf
To obtain it in English, go to:
http://www.immunize.org/vis/hib99.pdf
HEPATITIS B VACCINE VIS (dated 7/11/01)
To obtain a ready-to-print (PDF) version of the VIS for hepatitis B vaccine
in Burmese, go to:
http://www.immunize.org/vis/bu_hpb01.pdf
To obtain it in English, go to:
http://www.immunize.org/vis/hepb01.pdf
MMR VACCINE VIS (dated 1/15/03)
To obtain a ready-to-print (PDF) version of the VIS for MMR vaccine in
Burmese, go to:
http://www.immunize.org/vis/bu_mmr03.pdf
To obtain it in English, go to:
http://www.immunize.org/vis/mmr03.pdf
For information about the use of VISs, and for VISs in a total of 33
languages, visit IAC's VIS web section at
http://www.immunize.org/vis
---------------------------------------------------------------
Back to Top
(6 of 6)
June 13, 2005
MMWR CORRECTS DATA REPORTED ON TOTAL MORTALITY AND INFLUENZA AND PNEUMONIA
MORTALITY BETWEEN APRIL 1-MAY 27, 2005
CDC published "Errata: Vol. 54, Nos. 12-20" in the June 10 issue of MMWR.
The text of the correction is reprinted below, excluding three corrected
tables: (1) mortality data for New Orleans, (2) mortality totals for the
Southwest Central region (Arkansas, Louisiana, Oklahoma, and Texas), and (3)
mortality totals for 122 U.S. Cities.
***********************
In Table III, "Deaths in 122 U.S. cities," for week 12 (ending March 26,
2005) through week 20 (ending May 21, 2005), the total mortality from all
causes and mortality caused by pneumonia and influenza for New Orleans,
Louisiana, were incorrectly reported. . . .
[Three corrected tables follow.]
Corrected data also are available at
http://www.cdc.gov/mmwr/distrnds.html Select "Search Mortality Tables"
and MMWR year 2005 and MMWR weeks 12-20.
***********************
To access a web-text (HTML) version of the complete article, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5422a6.htm
To access a ready-to-print (PDF) version of this issue of MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5422.pdf
To receive a FREE electronic subscription to MMWR (which includes new ACIP
statements), go to:
http://www.cdc.gov/mmwr/mmwrsubscribe.html |
